Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Aaron E Miller

Showing results (31-40 of 69) with videos related to

Pageof 7
Sort By:
Multiple Sclerosis and Related Disorders|March 4, 2021
Perceptions of risk and adherence to care in MS patients during the COVID-19 pandemic: A cross-sectional studyYinan Zhang, Erin Staker, Gary Cutter, et al.
Neurology. Clinical Practice|August 31, 2016
Consensus opinion of US neurologists on practice patterns in RIS, CIS, and RRMS: Evolution of treatment practicesCarlo Tornatore, J Theodore Phillips, Omar Khan, et al.
Neurology. Clinical Practice|May 2, 2013
Practice patterns of US neurologists in patients with SPMS and PPMS: A consensus studyOmar Khan, Aaron E Miller, Carlo Tornatore, et al.
Neurology. Clinical Practice|May 2, 2013
Practice patterns of US neurologists in patients with CIS, RRMS, or RIS: A consensus studyCarlo Tornatore, J Theodore Phillips, Omar Khan, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|June 8, 2019
Characterizing lymphocyte counts and infection rates with long-term teriflunomide treatment: Pooled analysis of clinical trialsGiancarlo Comi, Aaron E Miller, Myriam Benamor, et al.
JAMA Neurology|October 26, 2020
Autologous Hematopoietic Stem Cell Transplant in Multiple Sclerosis: Recommendations of the National Multiple Sclerosis SocietyAaron E Miller, Tanuja Chitnis, Bruce A Cohen, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|April 29, 2022
Effects of teriflunomide treatment on cognitive performance and brain volume in patients with relapsing multiple sclerosis: Post hoc analysis of the TEMSO core and extension studiesTill Sprenger, Ludwig Kappos, Maria Pia Sormani, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|August 8, 2013
Constructing an adaptive care model for the management of disease-related symptoms throughout the course of multiple sclerosis--performance improvement CMEAaron E Miller, Bruce A Cohen, Stephen C Krieger, et al.
Journal of Clinical Neuroscience : Official Journal of the Neurosurgical Society of Australasia|October 24, 2018
Efficacy and safety of teriflunomide in Asian patients with relapsing forms of multiple sclerosis: A subgroup analysis of the phase 3 TOWER studyAaron E Miller, Xianhao Xu, Richard Macdonell, et al.
Multiple Sclerosis and Related Disorders|December 7, 2016
Comparing outcomes from clinical studies of oral disease-modifying therapies (dimethyl fumarate, fingolimod, and teriflunomide) in relapsing MS: Assessing absolute differences using a number needed to treat analysisMark S Freedman, Xavier Montalban, Aaron E Miller, et al.
Pageof 7

Showing results (31-40 of 69) with videos related to

Sort By:
Pageof 7
Multiple Sclerosis and Related Disorders|March 4, 2021
Perceptions of risk and adherence to care in MS patients during the COVID-19 pandemic: A cross-sectional studyYinan Zhang, Erin Staker, Gary Cutter, et al.
Neurology. Clinical Practice|August 31, 2016
Consensus opinion of US neurologists on practice patterns in RIS, CIS, and RRMS: Evolution of treatment practicesCarlo Tornatore, J Theodore Phillips, Omar Khan, et al.
Neurology. Clinical Practice|May 2, 2013
Practice patterns of US neurologists in patients with SPMS and PPMS: A consensus studyOmar Khan, Aaron E Miller, Carlo Tornatore, et al.
Neurology. Clinical Practice|May 2, 2013
Practice patterns of US neurologists in patients with CIS, RRMS, or RIS: A consensus studyCarlo Tornatore, J Theodore Phillips, Omar Khan, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|June 8, 2019
Characterizing lymphocyte counts and infection rates with long-term teriflunomide treatment: Pooled analysis of clinical trialsGiancarlo Comi, Aaron E Miller, Myriam Benamor, et al.
JAMA Neurology|October 26, 2020
Autologous Hematopoietic Stem Cell Transplant in Multiple Sclerosis: Recommendations of the National Multiple Sclerosis SocietyAaron E Miller, Tanuja Chitnis, Bruce A Cohen, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|April 29, 2022
Effects of teriflunomide treatment on cognitive performance and brain volume in patients with relapsing multiple sclerosis: Post hoc analysis of the TEMSO core and extension studiesTill Sprenger, Ludwig Kappos, Maria Pia Sormani, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|August 8, 2013
Constructing an adaptive care model for the management of disease-related symptoms throughout the course of multiple sclerosis--performance improvement CMEAaron E Miller, Bruce A Cohen, Stephen C Krieger, et al.
Journal of Clinical Neuroscience : Official Journal of the Neurosurgical Society of Australasia|October 24, 2018
Efficacy and safety of teriflunomide in Asian patients with relapsing forms of multiple sclerosis: A subgroup analysis of the phase 3 TOWER studyAaron E Miller, Xianhao Xu, Richard Macdonell, et al.
Multiple Sclerosis and Related Disorders|December 7, 2016
Comparing outcomes from clinical studies of oral disease-modifying therapies (dimethyl fumarate, fingolimod, and teriflunomide) in relapsing MS: Assessing absolute differences using a number needed to treat analysisMark S Freedman, Xavier Montalban, Aaron E Miller, et al.
Pageof 7